| 2.35 -0.05 (-2.08%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.27 | 1-year : | 3.67 |
| Resists | First : | 2.8 | Second : | 3.15 |
| Pivot price | 2.54 |
|||
| Supports | First : | 2.25 | Second : | 1.87 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 2.5 |
| MA(100) : | 2.58 |
MA(250) : | 2.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.2 |
D(3) : | 19.3 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 3.56 | Low : | 1.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IPHA ] has closed above bottom band by 10.6%. Bollinger Bands are 25% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.38 | 2.38 - 2.39 |
| Low: | 2.28 - 2.3 | 2.3 - 2.32 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Mon, 15 Apr 2024
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 - Manchestertimes
Mon, 15 Apr 2024
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 - Business Wire
Sun, 14 Apr 2024
Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update - MarketBeat
Sat, 13 Apr 2024
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Yahoo Movies Canada
Wed, 10 Apr 2024
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
Wed, 10 Apr 2024
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 ... - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 81 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 77 (K) |
| Shares Short P.Month | 78 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | -12.3 % |
| Operating Margin | -57.3 % |
| Return on Assets (ttm) | -4.1 % |
| Return on Equity (ttm) | -14.3 % |
| Qtrly Rev. Growth | 77.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | -0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -23.5 |
| PEG Ratio | 0 |
| Price to Book value | 3.67 |
| Price to Sales | 3.08 |
| Price to Cash Flow | -5.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|